Xenleta Now Available in New Oral Pack for Community-Acquired Bacterial Pneumonia

Xenleta^® (lefamulin) is now available in a 10-count oral pack (or “X” pack) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

The new 10-count oral pack provides a complete 5-day course of treatment. Xenleta is administered as a 600mg tablet orally every 12 hours for 5 days.

“This new package size offers pharmacies an option to expand product availability in a cost-effective way to service their local patients and physicians by providing patients a convenient package that contains a complete 5-day course of oral treatment for CABP,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. 

Xenleta, a pleuromutilin antibacterial, is also available as a 150mg/15mL single-dose vial for intravenous infusion.

Reference

Nabriva announces availability of Xenleta^® (lefamulin) in a 10-count oral pack. News release. Nabriva Therapeutics US, Inc. Accessed November 11, 2021. https://www.globenewswire.com/news-release/2021/11/11/2332502/37424/en/Nabriva-Announces-Availability-of-XENLETA-lefamulin-in-a-10-Count-Oral-Pack.html.